Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura M Jacobsen

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Diabetes Care|March 31, 2023
Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet AutoantibodiesJay M Sosenko, David Cuthbertson, Emily K Sims, et al.
Diabetes Technology & Therapeutics|August 25, 2020
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 DiabetesLaura M Jacobsen, Brian N Bundy, Madison N Greco, et al.
Diabetologia|November 27, 2019
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screeningLaura M Jacobsen, Laura Bocchino, Carmella Evans-Molina, et al.
Diabetologia|February 27, 2025
IA-2A positivity increases risk of progression within and across established stages of type 1 diabetesEmily K Sims, David Cuthbertson, Lauric A Ferrat, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 2025
Dietary patterns for weight and glycemic management in persons with type 1 diabetes: a meta-analysis of clinical trialsDaria Igudesman, Laura M Nally, Alyssa A Grimshaw, et al.
Diabetes Care|December 20, 2023
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 DiabetesTimothy P Foster, Laura M Jacobsen, Brittany Bruggeman, et al.
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|June 12, 2026
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect ProfileLaura M Jacobsen, Dave Cuthbertson, Jamie Felton, et al.
Diabetes Care|November 3, 2022
Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at ScreeningEmily K Sims, David Cuthbertson, Jamie L Felton, et al.
Diabetes Care|March 6, 2020
Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Diabetes Care|March 31, 2023
Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet AutoantibodiesJay M Sosenko, David Cuthbertson, Emily K Sims, et al.
Diabetes Technology & Therapeutics|August 25, 2020
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 DiabetesLaura M Jacobsen, Brian N Bundy, Madison N Greco, et al.
Diabetologia|November 27, 2019
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screeningLaura M Jacobsen, Laura Bocchino, Carmella Evans-Molina, et al.
Diabetologia|February 27, 2025
IA-2A positivity increases risk of progression within and across established stages of type 1 diabetesEmily K Sims, David Cuthbertson, Lauric A Ferrat, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 2025
Dietary patterns for weight and glycemic management in persons with type 1 diabetes: a meta-analysis of clinical trialsDaria Igudesman, Laura M Nally, Alyssa A Grimshaw, et al.
Diabetes Care|December 20, 2023
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 DiabetesTimothy P Foster, Laura M Jacobsen, Brittany Bruggeman, et al.
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|June 12, 2026
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect ProfileLaura M Jacobsen, Dave Cuthbertson, Jamie Felton, et al.
Diabetes Care|November 3, 2022
Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at ScreeningEmily K Sims, David Cuthbertson, Jamie L Felton, et al.
Diabetes Care|March 6, 2020
Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Pageof 8